Clinical Trial Update: Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study [Phase 3]

View source ↗

Summary

Phase 3 FLAIR study comparing subcutaneous versus intramuscular injections of long-acting cabotegravir and rilpivirine in adults with HIV-1 infection completed,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• cabotegravir (cabotegravir)
• rilpivirine (rilpivirine)

Snippet

Sponsor: ViiV Healthcare | Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) | Phase 3 | Status: COMPLETED | Results posted: 2024-11-26